Normal high-sensitivity cardiac troponin for ruling-out inpatient mortality in acute COVID-19
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0284523 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Alexander Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: University of St Andrews School of Medicine, St Andrews, United Kingdom. Hauptthemen laut MEDLINE: Troponin, COVID-19. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Assessment of inpatient mortality risk in COVID-19 patients is important for guiding clinical decision-making. High sensitivity cardiac troponin T (hs-cTnT) is a biomarker of cardiac injury associated with a worse prognosis in COVID-19. We explored how hs-cTnT could potentially be used in clinical practice for ruling in and ruling out mortality in COVID-19.
Method
We tested the diagnostic value of hs-cTnT in laboratory-confirmed COVID-19 patients (≥18 years old) admitted to the Royal Berkshire Hospital (UK) between 1 st March and 10 th May 2020. A normal hs-cTnT was defined as a value within the 99 th percentile of healthy individuals (≤14 ng/L), and an elevated hs-cTnT was defined as >14 ng/L. Adverse clinical outcome was defined as inpatient mortality related to COVID-19.
Results
A total of 191 COVID-19 patients (62% male; age 66±16 years) had hs-cTnT measured on admission. Of these patients, 124 (65%) had elevated hs-cTnT and 67 (35%) had normal hs-cTnT. On a group level, patients with elevated hs-cTnT had worse inpatient survival (p = 0.0014; Kaplan-Meier analysis) and higher risk of inpatient mortality (HR 5.84 [95% CI 1.29–26.4]; p = 0.02; Cox multivariate regression) compared to patients with normal hs-cTnT. On a per-patient level, a normal hs-cTnT had a negative predictive value of 94% (95% CI: 85–98%) for ruling out mortality, whilst an elevated hs-cTnT had a low positive predictive value of 38% (95% CI: 39–47%) for ruling in mortality.
Conclusions
In this study cohort of COVID-19 patients, the potential clinical utility of hs-cTnT appears to rest in ruling out inpatient mortality. This finding, if prospectively validated in a larger study, may allow hs-cTnT to become an important biomarker to facilitate admission-avoidance and early safe discharge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of St Andrews School of Medicine, St Andrews, United Kingdom.
- Royal Berkshire NHS Foundation Trust, Reading, United Kingdom.
- Royal Brompton Hospital, London, United Kingdom.
- Molecular and Clinical Sciences Research Institute, St George's University of London, London, United Kingdom.
- St George's, University of London, London, United Kingdom.
ORCID-Profile: Robert Hammond
Zitieren
APA
Liu, A., Hammond, R., Chan, K., Chukwuenweniwe, C., Johnson, R., Khair, D., Duck, E., Olubodun, O., Barwick, K., Banya, W., Stirrup, J., Donnelly, P. D., Kaski, J. C., & Coates, A. R. M. (2023). Normal high-sensitivity cardiac troponin for ruling-out inpatient mortality in acute COVID-19. PLOS ONE. https://doi.org/10.1371/journal.pone.0284523
Vancouver
Liu A, Hammond R, Chan K, Chukwuenweniwe C, Johnson R, Khair D, et al. Normal high-sensitivity cardiac troponin for ruling-out inpatient mortality in acute COVID-19. PLOS ONE. 2023. doi:10.1371/journal.pone.0284523
BibTeX
@article{Liu2023,
author = {Liu, Alexander and Hammond, Robert and Chan, Kenneth and Chukwuenweniwe, Chukwugozie and Johnson, Rebecca and Khair, Duaa and Duck, Eleanor and Olubodun, Oluwaseun and Barwick, Kristian and Banya, Winston and Stirrup, James and Donnelly, Peter D and Kaski, Juan Carlos and Coates, Anthony R M},
title = {Normal high-sensitivity cardiac troponin for ruling-out inpatient mortality in acute COVID-19},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0284523}
}
EUVIMED